Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 5 recruiting now early-phase tilt small index

Aneurysm: early-phase trial registry

5 of 7 indexed Aneurysm trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,497 of 28,707 conditions by registered trial count.

7 US clinical trials · 5 currently recruiting · #2,497 of 28,707 conditions by registered trial count

Aneurysm: 7 US clinical trials tracked, 5 recruiting.

Aneurysm is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Stryker Neurovascular, running 1 of these trials.

Enrollment posture brief

Registry condition aneurysm

OPEN 5 | RECR 71% | LATE 0 | EARLY 2 | RANK #2497 | SPON 1

Nearest open-share peer: Advanced Endometrial Carcinoma (71% recruiting · 7 trials)

ACL Tear71.4%Aneurysm (this)71%ACL57.1%Acute Myelogenous Leukemia42.9%Acne Scars28.6%
Open-enrollment share among volume-matched conditions near Aneurysm

Aneurysm lists 5 open slots (71% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Aneurysm on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Aneurysm is recruiting above its size-band peers.

    5 of 7 indexed trials (71.4%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Aneurysm trials is spread across many organizations.

    Stryker Neurovascular accounts for 1 of 7 trials (14.3%). 7 distinct sponsors appear on at least one study for this condition label.

  3. Typical Aneurysm enrolment sits around 183 participants.

    Median target enrolment is 183 among the 7 trials that report a genuine target (sentinel values excluded). 2 of those (28.6%) plan for fewer than 100 participants.

  4. Aneurysm splits between interventional and observational designs.

    4 interventional and 3 observational studies make up this index (57.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 21

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 1

Named interventions

Most-linked intervention names on Aneurysm records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Surpass Elite with Guardian Flow Diverter System Device
1 trials
Doxycycline Drug
1 trials
Gelweave Valsalva Vascular Graft Device
1 trials
Gelweave Vascular Graft Device
1 trials
Cardiovascular Patch Device
1 trials
Vascular Bypass Graft Device
1 trials
Gelsoft Plus Vascular Graft Device
1 trials
SHIELD Device
1 trials

US sites by state

Facility locations filed on Aneurysm trials. A trial with sites in several states counts in each.

Massachusetts 3 trials
California 3 trials
Pennsylvania 2 trials
New York 2 trials
Florida 2 trials
Arizona 2 trials
Washington 1 trials
Virginia 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Aneurysm page

7 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Aneurysm condition card totals 7 registered trials; most-linked intervention Surpass Elite with Guardian Flow Diverter System; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.